Breaking News Instant updates and real-time market news.

HMNY

Helios and Matheson

$0.07

-0.0029 (-4.15%)

, HL

Hecla Mining

$2.88

-0.05 (-1.71%)

08:45
08/09/18
08/09
08:45
08/09/18
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Helios and Matheson (HMNY) 90.24% +6.95, Hecla Mining (HL) 1.61% +0.68, Geron (GERN) 26.02% +0.37, Majesco (COOL) 44.04% +0.26, Zynga (ZNGA) 0.50% +0.08, Qudian (QD) 12.42% +0.05, db X trackers China (ASHR) 5.36% +0.04, 3D Systems (DDD) 4.01% +0.03, Applied Optoelectronics (AAOI) 7.09% +0.03, and Brookfield Property (BPY) 44.29% +0.03.

HMNY

Helios and Matheson

$0.07

-0.0029 (-4.15%)

HL

Hecla Mining

$2.88

-0.05 (-1.71%)

GERN

Geron

$3.86

-0.04 (-1.03%)

COOL

Ticker changed to PTE

$22.49

0.99 (4.60%)

ZNGA

Zynga

$3.94

-0.005 (-0.13%)

QD

Qudian

$6.90

-0.38 (-5.22%)

ASHR

X-trackers Harvest CSI 300

$24.60

-0.605 (-2.40%)

DDD

3D Systems

$17.93

4.35 (32.03%)

AAOI

Applied Optoelectronics

$40.85

3.54 (9.49%)

BPY

Brookfield Property

$19.93

-0.3 (-1.48%)

  • 09

    Aug

  • 13

    Aug

  • 14

    Aug

  • 15

    Aug

  • 16

    Aug

  • 24

    Aug

  • 04

    Sep

  • 17

    Sep

  • 18

    Sep

HMNY Helios and Matheson
$0.07

-0.0029 (-4.15%)

07/29/18
EROP
07/29/18
DOWNGRADE
EROP
Neutral
Helios and Matheson downgraded to Neutral from Buy at Euro Pacific
07/26/18
MAXM
07/26/18
INITIATION
MAXM
Hold
Helios and Matheson assumed with a Hold at Maxim
Maxim analyst Allen Klee assumed Helios and Matheson with a Hold rating, saying that while he remains optimistic about the potential for continued MoviePass subscriber growth, he is also cautious about the company's potential capital raising needs. Klee also sees the stock as a "high risk/reward" situation as it trades at 0.1-times his expected FY18 revenue estimate.
04/25/18
MAXM
04/25/18
INITIATION
Target $12
MAXM
Buy
Helios and Matheson assumed with a Buy at Maxim
Maxim analyst Nehal Chokshi assumed Helios and Matheson with a Buy rating but lowered his price target to $12 from $16 under the prior coverage. The analyst contends that survey findings suggest "overusage being contained to a sliver of subscribers" and believes the company can trade at $12 per share based on enterprise value of $1.4B is its MoviePass offering can show incremental traffic from occasional movie goers hitting just 1 movie ticket per month.
04/24/18
ADAM
04/24/18
NO CHANGE
Target $12
ADAM
Buy
Helios and Matheson price target lowered to $12 from $15 at Canaccord
Canaccord analyst Austin Moldow lowered his price target on Helios and Matheson to $12 from $15 following its recent capital raise. The analyst raised his revenue forecast, but it was more than offset by the higher share count given the company's capital raise and its at-the-market offering, where the company can sell shares in the open market at its discretion. Moldow maintained his Buy rating on Helios and Matheson shares.
HL Hecla Mining
$2.88

-0.05 (-1.71%)

07/24/18
JPMS
07/24/18
INITIATION
Target $5.5
JPMS
Overweight
Hecla Mining reinstated with an Overweight at JPMorgan
JPMorgan analyst John Bridges reinstated coverage of Hecla Mining with an Overweight rating and $5.50 price target. The rating is unchanged and the price target is lowered from $7.00 relative to his firm's prior coverage. The acquisition of Klondex's mines in Nevada increases Hecla's exposure to what could be the world's best location to invest in the resource sector, Bridges tells investors in a research note.
07/13/18
ADAM
07/13/18
DOWNGRADE
ADAM
Hold
Hecla Mining downgraded to Hold from Buy at Canaccord
03/20/18
ROTH
03/20/18
DOWNGRADE
Target $2.25
ROTH
Neutral
Klondex Mines downgraded to Neutral from Buy at Roth Capital
Roth Capital analyst Jake Sekelsky downgraded Klondex Mines (KLDX) to Neutral from Buy after the company announced a proposed acquisition by Hecla Mining (HL). The analyst also lowered his price target on Klondex's shares to $2.25 from $3.
03/20/18
RILY
03/20/18
NO CHANGE
Target $5.3
RILY
Buy
Hecla selloff brings favorable entry point, says B. Riley FBR
B. Riley FBR analyst Lucas Pipes believes the recent pullback in shares of Hecla Mining (HL) bring a favorable entry point. The analyst raised his price target for the shares to $5.30 from $5.00 following the acquisition of Klondex Mines (KLDX). He keeps a Buy rating on Hecla.
GERN Geron
$3.86

-0.04 (-1.03%)

03/19/18
PIPR
03/19/18
NO CHANGE
Target $7
PIPR
Overweight
Geron price target raised to $7 from $5 at Piper Jaffray
Piper Jaffray analyst Charles Duncan raised his price target for Geron to $7 after the company this morning reported year-end 2017 cash of $109M and provided an update on its IMerge and IMbark studies. The analyst projects the current cash will fund Geron's operations into 2020. He's encouraged by the update on the IMbark study in myelofibrosis and reiterates an Overweight rating on the shares.
07/05/18
RILY
07/05/18
INITIATION
Target $5.75
RILY
Buy
Geron initiated with a Buy at B. Riley FBR
B. Riley FBR analyst George Zavoico started Geron with a Buy rating and $5.75 price target.
COOL Ticker changed to PTE
$22.49

0.99 (4.60%)

06/27/18
CANT
06/27/18
NO CHANGE
Target $65
CANT
Overweight
Cantor says PolarityTE patent process ongoing, commercialization maturing
After hosting a conference call with PolarityTE management yesterday, Cantor Fitzgerald analyst Elemer Piros said that the company walked through the process of its interaction with the USPTO and explained that the patent process is ongoing, not finalized, and may take years. Meanwhile, SkinTE was commercialized in December 2017 via a limited market release and the company's commercialization efforts are maturing, said Piros, who reiterates an Overweight rating and $65 price target on PolarityTE shares.
06/25/18
CANT
06/25/18
NO CHANGE
Target $65
CANT
Overweight
Cantor reiterates Overweight rating on PolarityTE after meeting with doctors
After attending an event hosted by PolarityTE with Key Opinion Leaders and hearing three surgeons describe their clinical experiences using SkinTE, Cantor Fitzgerald analyst Elemer Piros said he believes PolarityTE is positioned long-term to "redefine the treatment landscape for wound regeneration." He believes the fact that the shares are trading down 33% may be due to the market's misunderstanding of the company's IP strategy and interaction with the U.S. Patent and Trademark Office. Piros' note to investors makes no mention of Citron Research, which earlier today accused PolarityTE of fraud related to its patent holdings and promotion of the patents to investors. Piros reiterates his Overweight rating and $65 price target on PolarityTE, which is down 32% to $26.42 in afternoon trading.
06/13/18
CANT
06/13/18
NO CHANGE
Target $65
CANT
Overweight
PolarityTE price target lowered to $65 from $70 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros lowered his price target for PolarityTE to $65 to reflect the company's recent financing. The analyst, however, left an investor tour at the company's Salt Lake City facilities with significant confidence for its "extensive" pipeline. The analyst believes PolarityTE looks well positioned to deliver on its objectives over the next 24 months. He reiterates an Overweight rating on the shares.
02/15/18
02/15/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Portland General Electric (POR) initiated with a Buy at Mizuho. 2. Arsanis (ASNS) initiated with an Overweight at Cantor Fitzgerald. 3. Cantor says PolarityTE (COOL) can revolutionize regenerative medicine. 4. Foundation Medicine (FMI) initiated with an Outperform at Cowen. 5. Box (BOX) initiated with a Buy at DA Davidson. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ZNGA Zynga
$3.94

-0.005 (-0.13%)

05/31/18
PIPR
05/31/18
NO CHANGE
Target $5
PIPR
Overweight
Zynga acquisition adds growing revenue stream, says Piper Jaffray
Piper Jaffray analyst Michael Olson says Zynga's $250M acquisition of Gram Games brings a profitably growing revenue stream. Gram brings a development team that has been responsible for several solid titles, including the company's most successful title, Merge Dragons, Olson tells investors in a research note. He believes Zynga is "building a pipeline of new titles and has several potential growth drivers." The analyst maintains an Overweight rating on the shares with a $5 price target.
05/31/18
BNCH
05/31/18
NO CHANGE
Target $5
BNCH
Buy
Zynga price target raised to $5 after Gram Games deal at Benchmark
Benchmark analyst Mike Hickey raised his price target on Zynga to $5 from $4.36 and reiterated his Buy rating after the company announced the acquisition of mobile game developer Gram Games. He contends the "swimmingly boring" deal should drive considerable EBITDA growth while leveraging Zynga's strength in established genres. Hickey also believes this and other potential M&A along with new game launches should help drive bookings growth and continued EBITDA acceleration.
08/01/18
BARD
08/01/18
NO CHANGE
Target $4
BARD
Neutral
Zynga Q2 results roughly in line, says Baird
Baird analyst Colin Sebastian kept his Neutral rating and $4 price target on Zynga after its Q2 results. The analyst notes that the 12% rise in bookings to $233.9M was above consensus of $230.4M thanks to continued growth in Mobile, while adjusted EBITDA of $43.6M was above consensus of about $40M. Sebastian adds that Zynga's "mobile momentum of forever franchises continues to increase, while cost efficiencies drive significant margin improvements" for the company.
QD Qudian
$6.90

-0.38 (-5.22%)

01/26/18
01/26/18
DOWNGRADE
Target $15

Hold
Qudian downgraded to Hold amid China cash loan industry turmoil at Stifel
As previously reported, Stifel analyst John Davis downgraded Qudian to Hold from Buy, stating that the near-term outlook is muddied by expected higher credit losses and a significant shift in business model due to the current turmoil in the Chinese cash loan industry. While he thinks Qudian will ultimately benefit from recent regulations in the form of reduced competition, he prefers to move to the sidelines "while the dust settles," he tells investors. Davis lowered his price target on Qudian shares to $15 from $19.
04/09/18
DBAB
04/09/18
INITIATION
DBAB
Hold
Qudian initiated with a Hold at Deutsche Bank
04/10/18
DBAB
04/10/18
INITIATION
Target $13.5
DBAB
Hold
Qudian initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Jacky Zuo started Qudian with a Hold rating and $13.50 price target.
05/22/18
NEED
05/22/18
NO CHANGE
Target $13
NEED
Buy
Qudian price target lowered to $13 from $20 at Needham
Needham analyst Mayank Tandon lowered his price target on Qudian to $13 to reflect the slump in shares after its Q1 results. The analyst believes however that the sell off, which is "likely related to the softness in the core cash business and the departure of two directors, appears overdone" given that the fundamentals of the business remain "intact". Tandon keeps his Buy rating on Qudian, noting that its auto financing business is ramping up and offsetting the cash credit performance with the sale of over 6.6K cars so far, which is "largely on track" with his estimates.
ASHR X-trackers Harvest CSI 300
$24.60

-0.605 (-2.40%)

DDD 3D Systems
$17.93

4.35 (32.03%)

07/26/18
07/26/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. PIPER CUTS 3D SYSTEMS TO UNDERWEIGHT: Piper Jaffray analyst Troy Jensen downgraded 3D Systems (DDD) to Underweight from Neutral with a $10 price target. He believes competition for the company's main product lines is intensifying. The analyst also thinks 3D will need to increase spending on direct sales, customer support and consulting, meaning "meaningful profitability" will likely be more challenged than revenue growth throughout 2018. He views the stock as overvalued. While Jensen continues to believe the overall 3D printing industry is "growing rapidly," he remains cautious on shares of 3D Systems and Stratasys (SSYS). He reiterated a Neutral rating on the latter. OPCO CUTS E.L.F. TO PERFORM: Oppenheimer analyst Rupesh Parikh downgraded e.l.f. Beauty (ELF) to Perform from Outperform saying the bull case is more uncertain from here. The analyst does not have a price target for the shares. Recent developments, including "still challenging trends" in the mass category and increased tariff uncertainty, bring greater risk to consensus forecasts, Parikh tells investors in a research note. He is harder-pressed to see the case for share outperformance. Ulta Beauty (ULTA) and Estee Lauder (EL) remain Parikh's top picks in beauty. FACEBOOK GETS MULTIPLE DOWNGRADES AFTER Q2 EARNINGS: Nomura Instinet analyst Mark Kelley downgraded Facebook (FB) to Neutral from Buy after the company delivered "underwhelming" Q2 results and guided for revenue growth deceleration through the end of the year. The revenue guidance paired with the expectation for mid-30% operating margins in the medium term or possibly longer means consensus numbers will be cut "drastically," he said. He lowered his price target on Facebook shares to $183 from $228. Facebook was also downgraded to Neutral from Buy by UBS analyst Eric Sheridan, who also lowered his price target for the shares to $180 from $212, and to Outperform from Strong Buy at Raymond James. Facebook shares are down over 19% in late morning trading. PIPER SAYS BIOGEN SELLOFF A BUYING OPPORTUNITY: Biogen (BIIB) shares "will recover and continue to work" into aducanumab's full Phase 3 data in 2020, Piper Jaffray analyst Christopher Raymond told investors. With the stock having run up into these data, the analyst said he understood the "sell-the-news" phenomenon. He believes, however, that the fundamental concerns he's heard from investors "don't seem to hold water." The analyst said to buy Biogen shares on the selloff. He kept an Overweight rating on the name with a $400 price target.
07/30/18
JPMS
07/30/18
NO CHANGE
Target $9.5
JPMS
Underweight
JPMorgan cautious on 3D printing names into Q2 results
JPMorgan analyst Paul Coster is cautious heading into the Q2 results for 3D printing pure-plays, 3D Systems (DDD) and Stratasys (SSYS). The analyst sees "intense" competition in every segment, and continued commoditization of the entry-level market segment. He has an Underweight rating on 3D with a $9.50 price target and Underweight rating on Stratasys with a $17 price target.
08/08/18
PIPR
08/08/18
NO CHANGE
Target $14
PIPR
Underweight
3D Systems price target raised to $14 from $10 at Piper Jaffray
Piper Jaffray analyst Troy Jensen raised his price target for 3D Systems to $14 saying the company reported "solid" Q2 results with revenue and earnings upside. Printer sales drove the revenue beat with sales growing 41% year-over-year despite only a modest contribution from the company's new printer portfolio, Jensen tells investors in a post-earnings research note. The analyst, however, believes 3D's operating expenses will continue to increase to fend off competition and launch its new line-up of printers. He reiterates an Underweight rating on the shares.
08/08/18
LOOP
08/08/18
NO CHANGE
Target $17
LOOP
Hold
3D Systems price target raised to $17 from $13 at Loop Capital
Loop Capital analyst Ananda Baruah raised his price target on 3D Systems to $17 after its Q2 results, noting the company reported a third consecutive quarter of "very solid" performance. The analyst states that 3D Systems is making "foundational" strides in positioning to generate revenue growth while broadening the use of 3D printing in the production market. Baruah also kept his Hold rating, saying that at 49-times forward earnings valuation multiple, the stock is "volatile and noisy while the business model normalizes".
AAOI Applied Optoelectronics
$40.85

3.54 (9.49%)

08/08/18
LOOP
08/08/18
NO CHANGE
Target $45
LOOP
Hold
Applied Optoelectronics price target raised to $45 from $32 at Loop Capital
Loop Capital analyst James Kisner raised his price target on Applied Optoelectronics to $45 after its "strong" Q2 results showed a surge in 100G data center revenue, even though its Q3 guidance was "somewhat mixed and impacted by new testing requirements". The analyst also cites the company's ability to maintain relatively high margin within a competitive environment, but keeps a Hold rating on the stock, calling for a longer history of exceeding expectations.
08/08/18
NEED
08/08/18
DOWNGRADE
Target $55
NEED
Buy
Applied Optoelectronics downgraded to Buy at Needham on valuation
As reported earlier, Needham analyst Alex Henderson downgraded Applied Optoelectronics to Buy from Strong Buy but raised his price target to $55 from $44 after its Q2 earnings beat and strong outlook for the second half of 2018. The analyst cites the rising revenue component of its 100G sales diminishing the bear thesis, with forecasted 100G volume expected to double in 2019 from 2018. Henderson also notes the management's view of normal pricing trends, with cost reduction expected to offset price declines in the second half of the year. The analyst notes however that after a 27% rise in the stock price afterhours, there is little upside to justify the Strong Buy rating.
08/08/18
CHLM
08/08/18
NO CHANGE
Target $28
CHLM
Sell
Applied Optoelectronics price target raised to $28 from $20 at Craig-Hallum
Craig-Hallum analyst Richard Shannon raised his price target for Applied Optoelectronics (AAOI) to $28 from $20 following a "strong" Q2 result, driven by strong upside from Data Center, specifically Facebook (FB). The analyst thinks most of the upside was from lack of supply from a competitor he believes to be Intel (INTC). He reiterates a Sell rating on Applied Optoelectronics shares.
08/08/18
NEED
08/08/18
DOWNGRADE
NEED
Buy
Applied Optoelectronics downgraded to Buy from Strong Buy at Needham
BPY Brookfield Property
$19.93

-0.3 (-1.48%)

03/27/18
JPMS
03/27/18
DOWNGRADE
Target $23.5
JPMS
Neutral
GGP downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Michael Mueller downgraded GGP (GGP) to Neutral and lowered his price target for the shares to $23.50 from $25.50. The analyst is shuffling his ratings in the REIT space following GGP's takeout by Brookfield Property Partners (BPY). He believes the price paid by Brookfield makes his "bullish mall thesis harder to push."
03/27/18
RHCO
03/27/18
DOWNGRADE
Target $23.5
RHCO
Hold
GGP downgraded to Hold from Buy at SunTrust
SunTrust analyst Ki Bin Kim downgraded GGP (GGP) to Hold from Buy and lowered the price target to $23.50 from $26 after Brookfield Property Partners (BPY) agreed to acquire the company at that price. While the improved offer represents only a "half-step" forward toward more equitable valuation relative to prior approach, the analyst ultimately expects this deal to close.
03/27/18
03/27/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. BB&T (BBT) upgraded to Buy from Neutral at B. Riley FBR and to Outperform from Market Perform at Wells Fargo. 2. Aratana Therapeutics (PETX) upgraded to Buy from Hold at Stifel with analyst Jonathan Block saying the early traction for Entyce, which was launched October 2017, has increased his conviction that the drug will act as the main revenue driver for Aratana in coming years. 3. Prologis (PLD) upgraded to Overweight from Neutral at JPMorgan with analyst Michael Mueller saying he is shuffling his ratings in the REIT space following GGP's (GGP) takeout by Brookfield Property Partners (BPY). 4. Brookfield Property (BPY) upgraded to Buy from Hold at Canaccord. 5. Roku (ROKU) upgraded to Neutral from Sell at Citi with analyst Mark May citing valuation for the upgrade following the stock's recent underperformance, but admits the upcoming lock-up expiration could serve as a negative catalyst. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/27/18
ADAM
03/27/18
UPGRADE
ADAM
Buy
Brookfield Property upgraded to Buy from Hold at Canaccord

TODAY'S FREE FLY STORIES

NVDA

Nvidia

$147.60

-4.38 (-2.88%)

, SFTBF

SoftBank

$0.00

(0.00%)

14:11
12/11/18
12/11
14:11
12/11/18
14:11
Periodicals
Breaking Periodicals news story on Nvidia, SoftBank »

SoftBank planning sale of…

NVDA

Nvidia

$147.60

-4.38 (-2.88%)

SFTBF

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 06

    Jan

CSCO

Cisco

$46.81

-0.05 (-0.11%)

14:10
12/11/18
12/11
14:10
12/11/18
14:10
Periodicals
Breaking Periodicals news story on Cisco »

Cisco in talks to acquire…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

  • 10

    Jan

CORT

Corcept Therapeutics

$12.66

-0.32 (-2.47%)

14:10
12/11/18
12/11
14:10
12/11/18
14:10
Hot Stocks
Corcept Therapeutics spikes in afternoon trading, jump 16% »

Corcept is up $2.04, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APTV

Aptiv

$66.34

1.01 (1.55%)

14:10
12/11/18
12/11
14:10
12/11/18
14:10
Hot Stocks
Aptiv CEO Kevin Clark purchases 11,310 shares of company stock »

Aptiv CEO Kevin Clark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSLR

First Solar

$42.08

-1.14 (-2.64%)

14:10
12/11/18
12/11
14:10
12/11/18
14:10
Options
Second day of short-term put buying in First Solar ahead of a company event »

Second day of short-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

BGG

Briggs & Stratton

$13.32

-0.32 (-2.35%)

14:05
12/11/18
12/11
14:05
12/11/18
14:05
Hot Stocks
Briggs & Stratton unit announces facility expansion for job site products »

Allmand Bros, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XPO

XPO Logistics

$66.32

0.42 (0.64%)

14:05
12/11/18
12/11
14:05
12/11/18
14:05
Options
XPO Logistics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COF

Capital One

$81.53

-0.93 (-1.13%)

, MCO

Moody's

$145.15

-0.75 (-0.51%)

13:55
12/11/18
12/11
13:55
12/11/18
13:55
Conference/Events
House Financial Services Committee to hold a hearing »

The Financial…

COF

Capital One

$81.53

-0.93 (-1.13%)

MCO

Moody's

$145.15

-0.75 (-0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 12

    Dec

GE

General Electric

$6.78

-0.145 (-2.10%)

13:50
12/11/18
12/11
13:50
12/11/18
13:50
Options
Put spread in General Electric may adjust downside position »

Put spread in General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KAI

Kadant

$82.62

1.19 (1.46%)

13:47
12/11/18
12/11
13:47
12/11/18
13:47
Upgrade
Kadant rating change  »

Kadant upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 20

    Dec

SHPG

Shire

$169.43

-0.69 (-0.41%)

13:39
12/11/18
12/11
13:39
12/11/18
13:39
Downgrade
Shire rating change  »

Shire downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Dec

PVTL

Pivotal Software

$18.04

0.01 (0.06%)

, AEO

American Eagle

$19.20

-0.32 (-1.64%)

13:35
12/11/18
12/11
13:35
12/11/18
13:35
Earnings
Notable companies reporting after market close »

Notable companies…

PVTL

Pivotal Software

$18.04

0.01 (0.06%)

AEO

American Eagle

$19.20

-0.32 (-1.64%)

PLAY

Dave & Buster's

$51.20

-1.32 (-2.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 11

    Dec

  • 14

    Dec

  • 19

    Dec

  • 20

    Dec

NURO

NeuroMetrix

$0.84

0.029 (3.58%)

, GSK

GlaxoSmithKline

$37.39

-0.29 (-0.77%)

13:32
12/11/18
12/11
13:32
12/11/18
13:32
Hot Stocks
NeuroMetrix reports agreement with GSK on 2019 Quell joint development program »

NeuroMetrix (NURO)…

NURO

NeuroMetrix

$0.84

0.029 (3.58%)

GSK

GlaxoSmithKline

$37.39

-0.29 (-0.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBS

CBS

$48.74

-1.04 (-2.09%)

13:30
12/11/18
12/11
13:30
12/11/18
13:30
Periodicals
CBS meeting adjourns without discussion of Moonves probe, NY Post says »

CBS stakeholders quickly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 19

    Dec

  • 20

    Dec

NBR

Nabors Industries

$2.79

0.03 (1.09%)

13:30
12/11/18
12/11
13:30
12/11/18
13:30
Options
Repeat call buying in Nabors »

Repeat call buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

TPR

Tapestry

$35.13

-0.68 (-1.90%)

13:25
12/11/18
12/11
13:25
12/11/18
13:25
Options
Tapestry call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARCT

Arcturus Therapeutics

$5.11

(0.00%)

13:25
12/11/18
12/11
13:25
12/11/18
13:25
Conference/Events
Arcturus Therapeutics to hold a conference call »

Key Opinion Leader…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

UBER

Uber

$0.00

(0.00%)

13:22
12/11/18
12/11
13:22
12/11/18
13:22
Periodicals
Uber being sued by defunct ride-hailing 'pioneer' Sidecar, Reuters says »

Sidecar Technologies, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
12/11/18
12/11
13:17
12/11/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALGN

Align Technology

$220.34

3.68 (1.70%)

13:17
12/11/18
12/11
13:17
12/11/18
13:17
Hot Stocks
Align Technology files three additional patent infringement suits against 3Shape »

Align Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
12/11/18
12/11
13:16
12/11/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
12/11/18
12/11
13:15
12/11/18
13:15
General news
Treasury's $38 B 3-year auction was fairly well received »

Treasury's $38 B…

13:15
12/11/18
12/11
13:15
12/11/18
13:15
General news
Treasury Action: the 3-year yield backed up from lows »

Treasury Action: the…

13:05
12/11/18
12/11
13:05
12/11/18
13:05
General news
3-Yr Note Auction CUSIP Number data reported »

3-Yr Note Auction CUSIP…

13:05
12/11/18
12/11
13:05
12/11/18
13:05
General news
3-Yr Note Auction Total Amount data reported »

3-Yr Note Auction Total…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.